{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:01:57Z","timestamp":1791266517600,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cervical cancer (CC) is the fourth most common cause of cancer-related death in women. According to international guidelines, a standard treatment for locally advanced cervical cancer (LACC) consists of exclusive concurrent chemoradiation treatment (CRT). However, chemoradioresistance and subsequent relapse and metastasis of cancer occur in many patients, and survival for these women has generally remained poor. Therefore, strategies to overcome resistance are urgently needed. We have recently reported a radiosensitizing effect of the signal transducer and activator of transcription 1 (STAT1) in CC, associated with the control of [Poly(ADP-ribose) polymerase \u22121] PARP1 levels, a key factor in cell response to DNA damage induced by radiation. Here, we sought to decipher the underlying mechanism of STAT1-mediated control of PARP1, elucidating its role as a radiosensitizer in CC. Functional and molecular biology studies demonstrated that STAT1 may act at both transcriptional and posttranscriptional levels to modulate PARP1 expression in CC cells. In light of these results, we tested the effect of Olaparib in sensitizing CC cells to radiation and investigated signaling pathways involved in the activity observed. Results showed that PARP1 inhibition, at clinically achievable doses, may indeed selectively improve the sensitivity of resistant CC cells to DNA-damaging treatment. The translational relevance of our findings was supported by preliminary results in a limited patient cohort, confirming that higher PARP1 levels are significantly associated with a radioresistant phenotype. Finally, bioinformatics analysis of GEPIA and TCGA databases, demonstrated that PARP1 mRNA is higher in CC than in normal tissues and that increased PARP1 mRNA expression levels are associated with poor prognosis of LACC patients. Overall, our data open new opportunities for the development of personalized treatments in women diagnosed with CC.<\/jats:p>","DOI":"10.1038\/s41419-021-04229-y","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T13:56:19Z","timestamp":1634046979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Stat1 confers sensitivity to radiation in cervical cancer cells by controlling Parp1 levels: a new perspective for Parp1 inhibition"],"prefix":"10.1038","volume":"12","author":[{"given":"Giuseppina","family":"Raspaglio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Buttarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Filippetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Buzzonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1918-1054","authenticated-orcid":false,"given":"Daniela","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"key":"4229_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin."},{"key":"4229_CR2","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1200\/JCO.2007.10.8324","volume":"25","author":"BJ Monk","year":"2007","unstructured":"Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol. 2007;25:2952\u201365.","journal-title":"J Clin Oncol."},{"key":"4229_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ygyno.2010.09.018","volume":"119","author":"DK Gaffney","year":"2010","unstructured":"Gaffney DK, Soisson AP. Simple or complex: optimal therapy for cancer of the cervix. Gynecol Oncol. 2010;119:401\u20133.","journal-title":"Gynecol Oncol."},{"key":"4229_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0140-6736(18)32470-X","volume":"393","author":"PA Cohen","year":"2019","unstructured":"Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393:169\u201382.","journal-title":"Lancet"},{"key":"4229_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.critrevonc.2019.02.009","volume":"137","author":"M Liontos","year":"2019","unstructured":"Liontos M, Kyriazoglou A, Dimitriadis I, Dimopoulos MA, Bamias A. Systemic therapy in cervical cancer: 30 years in review. Crit Rev Oncol Hematol. 2019;137:9\u201317.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4229_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s13046-019-1268-y","volume":"38","author":"M Buttarelli","year":"2019","unstructured":"Buttarelli M, Babini G, Raspaglio G, Filippetti F, Battaglia A, Ciucci A, et al. A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer. J Exp Clin Cancer Res. 2019;38:279.","journal-title":"J Exp Clin Cancer Res"},{"key":"4229_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1146\/annurev.immunol.15.1.563","volume":"15","author":"EA Bach","year":"1997","unstructured":"Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol. 1997;15:563\u201391.","journal-title":"Annu Rev Immunol."},{"key":"4229_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.semcancer.2019.10.002","volume":"60","author":"Y Verhoeven","year":"2020","unstructured":"Verhoeven Y, Tilborghs S, Jacobs J, De Waele J, Quatannens D, Deben C, et al. The potential and controversy of targeting STAT family members in cancer. Semin Cancer Biol. 2020;60:41\u201356.","journal-title":"Semin Cancer Biol."},{"key":"4229_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cyto.2015.11.011","volume":"89","author":"K Meissl","year":"2017","unstructured":"Meissl K, Macho-Maschler S, M\u00fcller M, Strobl B. The good and the bad faces of STAT1 in solid tumours. Cytokine. 2017;89:12\u201320.","journal-title":"Cytokine"},{"key":"4229_CR10","doi-asserted-by":"publisher","first-page":"6037","DOI":"10.2147\/OTT.S256708","volume":"13","author":"S Liu","year":"2020","unstructured":"Liu S, Imani S, Deng Y, Pathak JL, Wen Q, Chen Y, et al. Targeting IFN\/STAT1 pathway as a promising strategy to overcome radioresistance. Onco Targets Ther. 2020;13:6037\u201350.","journal-title":"Onco Targets Ther."},{"key":"4229_CR11","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.1074\/jbc.M302637200","volume":"279","author":"PA Townsend","year":"2004","unstructured":"Townsend PA, Scarabelli TM, Davidson SM, Knight RA, Latchman DS, Stephanou A. STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem. 2004;279:5811\u201320.","journal-title":"J Biol Chem."},{"key":"4229_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/jnci\/djj020","volume":"98","author":"S Xi","year":"2006","unstructured":"Xi S, Dyer KF, Kimak M, Zhang Q, Gooding WE, Chaillet JR, et al. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. J Natl Cancer Inst. 2006;98:181\u20139.","journal-title":"J Natl Cancer Inst."},{"key":"4229_CR13","first-page":"1603","volume":"234","author":"SY Wu","year":"2019","unstructured":"Wu SY, Chen CL, Tseng PC, Chiu CY, Lin YE, Lin CF. Fractionated ionizing radiation facilitates interferon-\u03b3 signaling and anticancer activity in lung adenocarcinoma cells. J Cell Physiol. 2019;234:1603\u201310.","journal-title":"J Cell Physiol"},{"key":"4229_CR14","doi-asserted-by":"publisher","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","volume":"8","author":"M Rose","year":"2020","unstructured":"Rose M, Burgess JT, O\u2019Byrne K, Richard DJ, Bolderson E. PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020;8:564601.","journal-title":"Front Cell Dev Biol"},{"key":"4229_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.radonc.2015.03.028","volume":"116","author":"CV Verhagen","year":"2015","unstructured":"Verhagen CV, de Haan R, Hageman F, Oostendorp TP, Carli AL, O\u2019Connor MJ, et al. Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015;116:358\u201365.","journal-title":"Radiother Oncol."},{"key":"4229_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/jcm9010064","volume":"9","author":"C Dubois","year":"2019","unstructured":"Dubois C, Martin F, Hassel C, Magnier F, Daumar P, Aubel C, et al. Low-dose and long-term olaparib treatment sensitizes MDA-MB-231 and SUM1315 triple-negative breast cancers spheroids to fractioned radiotherapy. J Clin Med. 2019;9:64.","journal-title":"J Clin Med."},{"key":"4229_CR17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3389\/fphar.2020.00170","volume":"11","author":"SA Jannetti","year":"2020","unstructured":"Jannetti SA, Zeglis BM, Zalutsky MR, Reiner T. Poly(ADP-Ribose)polymerase (PARP) inhibitors and radiation therapy. Front Pharmacol. 2020;11:170.","journal-title":"Front Pharmacol."},{"key":"4229_CR18","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.4049\/jimmunol.169.6.3046","volume":"169","author":"LF Barton","year":"2002","unstructured":"Barton LF, Cruz M, Rangwala R, Deepe GS Jr, Monaco JJ. Regulation of immunoproteasome subunit expression in vivo following pathogenic fungal infection. J Immunol. 2002;169:3046\u201352.","journal-title":"J Immunol."},{"key":"4229_CR19","doi-asserted-by":"publisher","first-page":"107985","DOI":"10.1016\/j.celrep.2020.107985","volume":"32","author":"M Gatti","year":"2020","unstructured":"Gatti M, Imhof R, Huang Q, Baudis M, Altmeyer M. The ubiquitin ligase TRIP12 limits PARP1 trapping and constrains PARP inhibitor efficiency. Cell Rep. 2020;32:107985.","journal-title":"Cell Rep."},{"key":"4229_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semcdb.2008.06.004","volume":"19","author":"G Regis","year":"2008","unstructured":"Regis G, Pensa S, Boselli D, Novelli F, Poli V. Ups and downs: the STAT1:STAT3 seesaw of interferon and gp130 receptor signalling. Semin Cell Dev Biol. 2008;19:351\u20139.","journal-title":"Semin Cell Dev Biol"},{"key":"4229_CR21","doi-asserted-by":"publisher","first-page":"e1007835","DOI":"10.1371\/journal.ppat.1007835","volume":"15","author":"EL Morgan","year":"2019","unstructured":"Morgan EL, Macdonald A. Autocrine STAT3 activation in HPV positive cervical cancer through a virus-driven Rac1-NF\u03baB-IL-6 signalling axis. PLoS Pathog. 2019;15:e1007835.","journal-title":"PLoS Pathog."},{"key":"4229_CR22","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1158\/1535-7163.MCT-05-0451","volume":"5","author":"SS Liu","year":"2006","unstructured":"Liu SS, Chan KY, Leung RC, Law HK, Leung TW, Ngan HY. Enhancement of the radiosensitivity of cervical cancer cells by overexpressing p73alpha. Mol Cancer Ther. 2006;5:1209\u201315.","journal-title":"Mol Cancer Ther."},{"key":"4229_CR23","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.molcel.2015.01.034","volume":"58","author":"P Bai","year":"2015","unstructured":"Bai P. Biology of poly(ADP-Ribose) polymerases: the factotums of cell maintenance. Mol Cell. 2015;58:947\u201358.","journal-title":"Mol Cell"},{"key":"4229_CR24","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1099\/0022-1317-81-3-695","volume":"81","author":"KY Kim","year":"2000","unstructured":"Kim KY, Blatt L, Taylor MW. The effects of interferon on the expression of human papillomavirus oncogenes. J Gen Virol. 2000;81:695\u2013700.","journal-title":"J Gen Virol."},{"key":"4229_CR25","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1093\/emboj\/19.21.5720","volume":"19","author":"Y Kabeya","year":"2000","unstructured":"Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19:5720\u201328.","journal-title":"EMBO J."},{"key":"4229_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4143\/crt.2013.159","volume":"47","author":"GH Jo","year":"2015","unstructured":"Jo GH, B\u00f6gler O, Chwae YJ, Yoo H, Lee SH, Park JB, et al. Radiation-induced autophagy contributes to cell death and induces apoptosis partly in malignant glioma cells. Cancer Res Treat. 2015;47:221\u201341.","journal-title":"Cancer Res Treat."},{"key":"4229_CR27","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.clon.2017.03.002","volume":"29","author":"LH Cossar","year":"2017","unstructured":"Cossar LH, Schache AG, Risk JM, Sacco JJ, Jones NJ, Lord R. Modulating the DNA damage response to improve treatment response in cervical cancer. Clin Oncol. 2017;29:626\u201334.","journal-title":"Clin Oncol."},{"key":"4229_CR28","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.4049\/jimmunol.1100040","volume":"187","author":"S Brzostek-Racine","year":"2011","unstructured":"Brzostek-Racine S, Gordon C, Van Scoy S, Reich NC. The DNA damage response induces IFN. J Immunol. 2011;187:5336\u201345.","journal-title":"J Immunol."},{"key":"4229_CR29","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1124\/mol.111.075994","volume":"81","author":"J Hussner","year":"2012","unstructured":"Hussner J, Ameling S, Hammer E, Herzog S, Steil L, Schwebe M, et al. Regulation of interferon-inducible proteins by doxorubicin via interferon gamma-Janus tyrosine kinase-signal transducer and activator of transcription signaling in tumor cells. Mol Pharmacol. 2012;81:679\u201388.","journal-title":"Mol Pharmacol."},{"key":"4229_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/bjc.2015.398","volume":"114","author":"ME Legrier","year":"2016","unstructured":"Legrier ME, Bi\u00e8che I, Gaston J, Beurdeley A, Yvonnet V, D\u00e9as O, et al. Activation of IFN\/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer. Br J Cancer. 2016;114:177\u201387.","journal-title":"Br J Cancer"},{"key":"4229_CR31","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1096\/fj.10-160895","volume":"25","author":"J Li","year":"2011","unstructured":"Li J, Powell SR, Wang X. Enhancement of proteasome function by PA28\u03b1 overexpression protects against oxidative stress. FASEB J. 2011;25:883\u201393.","journal-title":"FASEB J."},{"key":"4229_CR32","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.immuni.2015.04.014","volume":"42","author":"K Hirahara","year":"2015","unstructured":"Hirahara K, Onodera A, Villarino AV, Bonelli M, Scium\u00e8 G, Laurence A, et al. Asymmetric action of STAT transcription factors drives transcriptional outputs and cytokine specificity. Immunity. 2015;42:877\u201389.","journal-title":"Immunity"},{"key":"4229_CR33","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.4049\/jimmunol.175.6.3637","volume":"175","author":"X Hu","year":"2005","unstructured":"Hu X, Park-Min KH, Ho HH, Ivashkiv LB. IFN-gamma-primed macrophages exhibit increased CCR2-dependent migration and altered IFN-gamma responses mediated by Stat1. J Immunol. 2005;175:3637\u201347.","journal-title":"J Immunol."},{"key":"4229_CR34","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1158\/1535-7163.MCT-13-0338","volume":"12","author":"HJ Lee","year":"2013","unstructured":"Lee HJ, Yoon C, Schmidt B, Park DJ, Zhang AY, Erkizan HV, et al. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage. Mol Cancer Ther. 2013;12:2591\u2013600.","journal-title":"Mol Cancer Ther"},{"key":"4229_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.dnarep.2017.11.004","volume":"61","author":"P Gravells","year":"2018","unstructured":"Gravells P, Neale J, Grant E, Nathubhai A, Smith KM, James DI, et al. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: a comparison with the PARP1\/2\/3 inhibitor olaparib. DNA Repair. 2018;61:25\u201336.","journal-title":"DNA Repair"},{"key":"4229_CR36","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.3390\/ijms14023773","volume":"14","author":"L Shunkwiler","year":"2013","unstructured":"Shunkwiler L, Ferris G, Kunos C. Inhibition of poly(ADP-Ribose) polymerase enhances radiochemosensitivity in cancers proficient in DNA double-strand break repair. Int J Mol Sci. 2013;14:3773\u201385.","journal-title":"Int J Mol Sci"},{"key":"4229_CR37","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/cncr.32600","volume":"126","author":"JM Santiago-O\u2019Farrill","year":"2020","unstructured":"Santiago-O\u2019Farrill JM, Weroha SJ, Hou X, Oberg AL, Heinzen EP, Maurer MJ, et al. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. Cancer. 2020;126:894\u2013907.","journal-title":"Cancer"},{"key":"4229_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-017-0795-y","volume":"12","author":"SY Tam","year":"2017","unstructured":"Tam SY, Wu VW, Law HK. Influence of autophagy on the efficacy of radiotherapy. Radiat Oncol. 2017;12:57.","journal-title":"Radiat Oncol."},{"key":"4229_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2724-5","volume":"11","author":"M Noguchi","year":"2020","unstructured":"Noguchi M, Hirata N, Tanaka T, Suizu F, Nakajima H, Chiorini JA. Autophagy as a modulator of cell death machinery. Cell Death Dis. 2020;11:517.","journal-title":"Cell Death Dis."},{"key":"4229_CR40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fcell.2020.00041","volume":"8","author":"J Sia","year":"2020","unstructured":"Sia J, Szmyd R, Hau E, Gee HE. Molecular mechanisms of radiation-induced cancer cell death: a primer. Front Cell Dev Biol. 2020;8:41.","journal-title":"Front Cell Dev Biol."},{"key":"4229_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00432-018-2774-6","volume":"145","author":"S Camero","year":"2019","unstructured":"Camero S, Ceccarelli S, De Felice F, Marampon F, Mannarino O, Camicia L, et al. PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines. J Cancer Res Clin Oncol. 2019;145:137\u201352.","journal-title":"J Cancer Res Clin Oncol."},{"key":"4229_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13232-3","volume":"7","author":"CB Prasad","year":"2017","unstructured":"Prasad CB, Prasad SB, Yadav SS, Pandey LK, Singh S, Pradhan S, et al. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. Sci Rep. 2017;7:12876.","journal-title":"Sci Rep."},{"key":"4229_CR43","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ygyno.2019.08.010","volume":"155","author":"A Bianchi","year":"2019","unstructured":"Bianchi A, Lopez S, Altwerger G, Bellone S, Bonazzoli E, Zammataro L, et al. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecol Oncol. 2019;155:144\u201350.","journal-title":"Gynecol Oncol."},{"key":"4229_CR44","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1038\/onc.2013.352","volume":"33","author":"J Michels","year":"2014","unstructured":"Michels J, Vitale I, Saparbaev M, Castedo M, Kroemer G. Predictive biomarkers for cancer therapy with PARP inhibitors. Oncogene. 2014;33:3894\u2013907.","journal-title":"Oncogene"},{"key":"4229_CR45","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1158\/1535-7163.MCT-19-0520","volume":"18","author":"AR Michmerhuizen","year":"2019","unstructured":"Michmerhuizen AR, Pesch AM, Moubadder L, Chandler BC, Wilder-Romans K, Cameron M, et al. PARP1 inhibition radiosensitizes models of inflammatory breast cancer to ionizing radiation. Mol Cancer Ther. 2019;18:2063\u201373.","journal-title":"Mol Cancer Ther"},{"key":"4229_CR46","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3390\/cancers13020353","volume":"13","author":"P Matarrese","year":"2021","unstructured":"Matarrese P, Vona R, Ascione B, Paggi MG, Mileo AM. Physical interaction between HPV16E7 and the actin-binding protein gelsolin regulates epithelial-mesenchymal transition via HIPPO-YAP axis. Cancers. 2021;13:353.","journal-title":"Cancers"},{"key":"4229_CR47","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/09553000801953342","volume":"84","author":"JR Williams","year":"2008","unstructured":"Williams JR, Zhang Y, Zhou H, Gridley DS, Koch CJ, Russell J, et al. A quantitative overview of radiosensitivity of human tumor cells across histological type and TP53 status. Int J Radiat Biol. 2008;84:253\u201364.","journal-title":"Int J Radiat Biol."},{"key":"4229_CR48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/00000421-198202000-00015","volume":"5","author":"A Dritschilo","year":"1982","unstructured":"Dritschilo A, Mossman K, Gray M, Sreevalsan T. Potentiation of radiation injury by interferon. Am J Clin Oncol. 1982;5:79\u201382.","journal-title":"Am J Clin Oncol."},{"key":"4229_CR49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1089\/jir.2005.25.20","volume":"25","author":"CM Robinson","year":"2005","unstructured":"Robinson CM, Hale PT, Carlin JM. The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res. 2005;25:20\u201330.","journal-title":"J Interferon Cytokine Res."},{"key":"4229_CR50","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1093\/nar\/23.23.4878","volume":"23","author":"K Quandt","year":"1995","unstructured":"Quandt K, Frech K, Karas H, Wingender E, Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res. 1995;23:4878\u201384.","journal-title":"Nucleic Acids Res"},{"key":"4229_CR51","unstructured":"Munshi A, Hobbs M, Meyn RE. Clonogenic cell survival assay. In: Blumenthal RD, editor. Chemosensitivity: volume 1 in vitro assays. New Jersey: Humana Press; 2005. p. 21\u20138."},{"key":"4229_CR52","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13046-020-01775-9","volume":"39","author":"M De Donato","year":"2020","unstructured":"De Donato M, Babini G, Mozzetti S, Buttarelli M, Ciucci A, Arduini G, et al. KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer. J Exp Clin Cancer Res. 2020;39:265.","journal-title":"J Exp Clin Cancer Res."},{"key":"4229_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2002-3-7-research0034","volume":"3","author":"J Vandesompele","year":"2002","unstructured":"Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034.","journal-title":"Genome Biol."},{"key":"4229_CR54","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"4229_CR55","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov."},{"key":"4229_CR56","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.","journal-title":"Sci Signal"},{"key":"4229_CR57","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98\u2013102.","journal-title":"Nucleic Acids Res."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04229-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04229-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04229-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T09:14:34Z","timestamp":1669972474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04229-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":57,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["4229"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-04229-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"assertion":[{"value":"19 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"933"}}